Seminars in Oncology
Volume 30, Issue 2 , Pages 161-164 , April 2003

Dysregulation of apoptosis in Waldenstrom's macroglobulinemia does not involve nuclear factor kappa B activation

References 

  1. Owen RG, Barrans SL, Richards SJ, et al.  Waldenström macroglobulinemia: Development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol. 2001;116:420–428
  2. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al.  Waldenström's macroglobulinemia: Clinical featurs, complications, and management. J Clin Oncol. 2000;18:214–226
  3. Owen RG, Johnson SA, Morgan GJ. Waldenström's macroglobulinaemia: Laboratory diagnosis and treatment. Haematol Oncol. 2000;18:41–49
  4. Rayet B, Gelinas C. Aberrant Rel/NFκB genes and activity in human cancer. Oncogene. 1999;18:6938–6947
  5. Barkett M, Gilmore T. Control of apoptosis by Rel/NFκB transcription factors. Oncogene. 1999;18:6910–6924
  6. Dierlamm J, Baens M, Wlodarska I, et al.  The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the (11;18)(q21;q21) associated with MALT lymphomas. Blood. 1999;93:3601–3609
  7. Uren AG, O'Rourke K, Aravind L, et al.  Identification of paracaspases and metacaspases: Two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol Cell. 2000;6:961–967
  8. Lucas PC, Yonezumi M, Inohara N, et al.  Bcl10 and MALT1, Independent targets of chromosomal translocation in MALT lymphoma, co-operate in a novel NFκB signaling pathway. J Biol Chem. 2001;276:19012–19019
  9. Gasgoyne RD. The molecular biology of MALT lymphoma. In:  Schechter GP,  Broudy VC,  Williams ME editor. Hematology 2001: American Society of Hematology Education Program. Washington, DC: ASH; 2001;p. 244–248
  10. Maes B, Demunter A, Peeters B, et al.  Bcl-10 mutation does not represent an important pathogenic mechanism in gastric MALT-type lymphoma, and the presence of the API2-MLT fusion is associated with aberrant nuclear Bcl-10 expression. Blood. 2002;99:1398–1404
  11. Hirase N, Yufa Y, Abe I, et al.  Primary macroglobulinemia with t(11,18) (q21,q21). Cancer Genet Cytogenet. 2000;117:113–117
  12. Hideshima T, Richardson P, Chauhan D, et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071–3076
  13. Mitsiades N, Mitsiades CS, Poulaki V, et al.  Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: Therapeutic applications. Blood. 2002;99:4079–4086
  14. LeBlanc R, Catley LP, Hideshima T, et al.  Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002;62:4996–5000
  15. Elliott PJ, Ross JS. The proteasome: A new target for novel drug therapies. Am J Clin Pathol. 2001;116:637–646
  16. Leitch D, O'Connor SJM, Barrans SL, et al.  Waldenström's macroglobulinemia is characterised by a memory B-cell immunophenotype and the absence of immunoglobulin translocations. Blood. 2002;100(suppl 1):347a; abstr)
  17. Cogswell P, Guttridge D, Funkhouser W, et al.  Selective activation of NFκB subunits in human breast cancer: Potential roles for NFκB2/p52 and for bcl-3. Oncogene. 2000;19:1123–1131
  18. Zhong H, Voll R, Ghosh S. Phosphorylation of NFκB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the co-activator CBP/p300. Mol Cell. 1998;1:661–671
  19. Schop RFJ, Kuehl WM, Van Wier SA, et al.  Waldenström's macroglobulinemia neoplastic cells lack IgH translocations but have frequent 6q deletions. Blood. 2002;100:2996–3001

☆ Address reprint requests to Dr Roger G. Owen, HMDS Laboratory, The General Infirmary at Leeds, Great George Street, Leeds, UK LS1 3EX.

☆☆ 0093-7754/03/3002-0014$30.00/0

PII: S0093-7754(03)70069-4

doi: 10.1053/sonc.2003.50049

Seminars in Oncology
Volume 30, Issue 2 , Pages 161-164 , April 2003

Article Tools

* Image Usage & Resolution